Advisory Board (Pharma)

What is an advisory board?

Why advisory boards matter in Medical Affairs

Advisory boards are one of the few structured mechanisms Medical Affairs has for gathering deliberate, expert input rather than passively collecting field insight over time. A well-run board can surface an evidence gap, stress-test a scientific narrative, or validate a real-world evidence question in a single session that might otherwise take months of scattered field observations to identify.

They also carry genuine regulatory weight. Because advisors are compensated for their time and expertise, advisory boards sit inside a compliance framework — not a gray area — and getting that framework wrong exposes the organization to real transparency and enforcement risk, not just a poorly-run meeting.

Types of advisory boards

• Scientific/clinical advisory boards: Focused on trial design, mechanism of action, or emerging clinical questions, typically with HCP KOLs and trial investigators.
• Market access/payer advisory boards: Convene payer-side experts to stress-test value dossiers, pricing narratives, or reimbursement strategy.
• Patient advisory boards: Include patient advocates or patient advisory group representatives to surface unmet needs and treatment-experience gaps that clinical endpoints don't capture.
• National, regional, or global boards: Scoped by geography to reflect local practice patterns, regulatory environments, and market dynamics.

Format: from in-person to hybrid

Advisory boards have moved from purely in-person meetings to a hybrid model: a synchronous video session, usually capped around 90 minutes, combined with an asynchronous phase where advisors review materials and respond to structured prompts over days or weeks. The synchronous portion handles real-time debate and consensus-building; the asynchronous portion tends to surface more considered input, particularly from advisors who don't speak first in a live discussion.

Compliance requirements

Advisory boards operate under industry codes of practice — including those from IFPMA, EFPIA, PhRMA, and ABPI — which require that advisors be selected based on relevant expertise, not relationship history, and that the meeting objective be documented before outreach begins. In the United States, compensation must reflect Fair Market Value (FMV), and payments are subject to Sunshine Act / Open Payments transparency reporting. Getting this right requires accurate advisor records — credentials, license status, NPI validation, contracted rates, and disclosures — assembled before, not after, the meeting.

How TikaMobile helps

TikaMobile connects advisory board output to the same insight pipeline your MSLs already use, so a concern raised by an advisor and a concern raised in the field on the same clinical question don't sit in two disconnected systems.

• Unified insight taxonomy: Advisory board insights are classified by therapeutic area, evidence-gap type, and stakeholder — the same schema used for field-captured MSL insight — inside one system.
• Advisor and KOL profiles in one place: No separate advisor database to reconcile against your KOL records; advisory board participants live in the same profile system as every other stakeholder your team engages.
• Compliant by design: Built-in tracking for engagement documentation supports the audit trail advisory board compliance requires.
• Traceability from insight to action: Advisory board findings route into the same evidence-generation and scientific-exchange workflows as any other field-captured insight.

Explore TikaMobile's KOL Engagement platform →

Related: Key Opinion Leader (KOL) · Medical Insights · Patient-Reported Outcomes (PRO) · Payer